Novel Indolylindazolylmaleimides as Inhibitors of Protein Kinase C-β:  Synthesis, Biological Activity, and Cardiovascular Safety

Novel indolylindazolylmaleimides were synthesized and examined for kinase inhibition. We identified low-nanomolar inhibitors of PKC-β with good to excellent selectivity vs other PKC isozymes and GSK-3β. In a cell-based functional assay, 8f and 8i effectively blocked IL-8 release induced by PKC-βII (...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of medicinal chemistry 2005-03, Vol.48 (6), p.1725-1728
Hauptverfasser: Zhang, Han-Cheng, Derian, Claudia K, McComsey, David F, White, Kimberly B, Ye, Hong, Hecker, Leonard R, Li, Jian, Addo, Michael F, Croll, Diane, Eckardt, Annette J, Smith, Charles E, Li, Quan, Cheung, Wai-Man, Conway, Bruce R, Emanuel, Stuart, Demarest, Keith T, Andrade-Gordon, Patricia, Damiano, Bruce P, Maryanoff, Bruce E
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Novel indolylindazolylmaleimides were synthesized and examined for kinase inhibition. We identified low-nanomolar inhibitors of PKC-β with good to excellent selectivity vs other PKC isozymes and GSK-3β. In a cell-based functional assay, 8f and 8i effectively blocked IL-8 release induced by PKC-βII (IC50 = 20−25 nM). In cardiovascular safety assessment, representative lead compounds bound to the hERG channel with high affinity, potently inhibited ion current in a patch-clamp experiment, and caused a dose-dependent increase of QTc in guinea pigs.
ISSN:0022-2623
1520-4804
DOI:10.1021/jm049478u